More than $100 million in Affordable Care Act funding is being awarded to 17 national, regional, and state hospital associations and health system organizations to assist efforts to reduce hospital-acquired conditions and readmissions.
Since 2011, preventable hospital-acquired conditions have been reduced 40% and 30-day readmissions are down by 20%, and CMS has made funding available to hospital associations and health systems around the country to continue efforts at reducing those numbers further.
More than $100 million in Affordable Care Act (ACA) funding is being awarded to 17 national, regional, and state hospital associations and health system organizations to assist efforts to reduce hospital-acquired conditions and readmissions.
“We have made significant progress in keeping patients safe and we are focused on accelerating improvement efforts through collaboration and reliable implementation of best practices,” Patrick Conway, MD, CMS acting principal deputy administrator and chief medical officer, said in a statement. “This second round of Hospital Engagement Networks will allow us to continue to improve health care safety across the nation.”
The funding is available through the second round of the Hospital Engagement Networks, part of the Partnership for Patients initiative.
HHS reported last year that efforts to improve patient safety in hospitals had resulted in 1.3 million fewer adverse events harming patients in 2011, 2012, and 2013. Additionally, approximately 50,000 fewer patients are dying in the hospital as a result of the reduction to hospital-acquired conditions and the industry saved roughly $12 billion in healthcare costs.
CMS reported that overall, initiatives born out of the ACA, like the Partnership for Patients, accountable care organizations, quality improvement organizations, and others have helped reduce hospital readmissions in Medicare by nearly 8% between January 2012 and December 2013.
Patient safety has taken the spotlight this lately. Earlier this week, the National Academy of Medicine released a report calling for paying more attention to getting diagnoses right and faster. Diagnostic errors are responsible for 6% to 7% of hospital adverse events and contribute to roughly 10% of patient deaths.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More